Hard To Treat Diseases logo

Hard To Treat Diseases(OTC) HTDS

Market Cap$5.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year+0%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Hard To Treat Diseases last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-07
Hard To Treat Diseases stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-30
1 month+0%USD 0.002026-09-04
3 month+0%USD 0.002026-07-07
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-10-07
3 year+0%USD 0.002023-10-03
5 year+0%USD 0.002021-10-08
Since inception-99.96%USD 0.002009-02-20

Hard To Treat Diseases Financials at a Glance

Market Cap

$5.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

10.63 (High)

Price

$0.00

Volume

30,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

HTDS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hard To Treat Diseases

Hard to Treat Diseases Inc. is a biotechnology company focused on developing, manufacturing, and exporting biopharmaceutical products and vaccines. Founded in 2009 and headquartered in Shenzhen, China, the company offers a diverse portfolio of biological agents and chemical pharmaceuticals.

Products and Services
  • Biopharmaceuticals including reteplase and mycobacterium vaccae
  • Chemical pharmaceuticals such as dasatinib tablets and imipenem
  • Vaccines for rabies, influenza, and Hepatitis A
Growth Outlook
  • Expanding sales network in South Asia and Southeast Asia
  • Increasing demand for vaccines in emerging markets
  • Focus on innovative biopharmaceuticals to capture market share
Financial Highlights
  • Market capitalization of $109,647 indicates growth potential
  • Stock price range between $0.000001 and $0.00002 shows stability
  • Beta of 0.769 suggests lower volatility compared to the market
Hard to Treat Diseases Inc. operates in a competitive biotechnology sector, with a strong emphasis on innovative solutions for healthcare challenges. The company's diverse product offerings position it well to meet the growing demand for biopharmaceuticals and vaccines, particularly in emerging markets. The recent financial data reflects a stable market presence, with a focus on expanding its sales network and product portfolio. Investors may find the company's strategic direction and market positioning appealing as it continues to navigate the evolving landscape of the biotechnology industry.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Clearwater, FL 33762, US

HTDS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$5.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.48B

Volume

30.00K

Avg. Volume

448.06K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Hard To Treat Diseases Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$5.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RGMPRegnum Corp.
$0.00+0.00%
IMEXFImagin Medical Inc.
$0.00+0.00%
GBLXGB Sciences, Inc.
$0.00+0.00%
PBLAPanbela Therapeutics, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.12+0.55%
NUNu Holdings
$15.58-0.51%
NVDANvidia
$237.47-0.74%
BULLWebull
$5.89-19.09%

Questions About HTDS

What is the current price of Hard To Treat Diseases?

Hard To Treat Diseases is trading at $0.00 per share.

What is the 52-week range for Hard To Treat Diseases?

Over the past 52 weeks, Hard To Treat Diseases has traded between $0.00 and $0.00.

How much debt does Hard To Treat Diseases have?

Hard To Treat Diseases total debt is unavailable.

How much cash does Hard To Treat Diseases have on hand?

Hard To Treat Diseases does not have cash on hand data available.

What is Hard To Treat Diseases’s dividend yield?

Hard To Treat Diseases does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services